Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This enables research which previously could not be done and lowers costs. The technology drives precision medicine by improving the understanding of the interaction of proteins and human disease.
Olink
Overview
Olink at a glance
Key developments 2022
In 2022, Olink had strong operational performance with a number of material, positive outputs. From a customer perspective, Olink’s base has grown from >630 to >850 biopharma and prestigious academic institutions. In biopharma, Olink has expanded its customer base from all of the top 20 institutitions to many of the top 40.
Sector
Life science
Location
Sweden
SDG aligment
Revenue (EURm)
% change from '21-'22
2022
+0%
131
2021
84
2020
49
Environmental
Carbon intensity: Tons CO₂e per EUR m revenue
Total tons CO₂ emitted
Change from '21-'22
2022
+0%
1 522
2021
495
Increase from 2021 to 2022 is mainly driven by the acquistion of Plasteurop"
Monetized climate impact
EURm
The figure represents the monetized value the company has on the environment. See chapter 4 for methodology.
Social
Full time employees
Turnover12%
Unadjusted gender pay gap22%
Gender balance 2022
%
Board
%
Management
%
All employees
Monetized employment impact
EURm
The figure represents the monetized value the company has as a quality employer. See chapter 4 for methodology.
Governance
Via Summa Compliance
%
✔ Code of conduct
✔ Supplier code of conduct
✔ Economic Sanctions
✔ Competition Law/Antitrust
✔ Data Protection/IT Security
✔ Anti-curruption
✔ Whistleblower
How Olink is advancing ESG
Olink has initiated a process to strengthen their sustainability efforts. With the support of external sustainability experts, Olink conducted initial analyses about Olink’s sustainability impact, realizing their first sustainability report in 2021 and expanded with a materiality analysis during 2022.
What are the challenges Olink addresses?
0%
of patients receive no benefit from treatment with top 10 best-selling drugs in the world
0%
of OECD GDP is spent on healthcare
How does Olink help?
Reality today
We do not understand the biology of many leading diseases—in particular the role of proteins—which prevents us from developing effective medication and delivering precision treatment.
Olink approach
Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to efficiently analyze large numbers of proteins with high throughput analysis, advancing our understanding of protein interactions in human diseases and our ability to develop new therapies.
Aspirational future
Deeper understanding of human biology and disease allows us to develop and deliver the most effective treatments for patients.
What impact does Olink create?
Number of publications
Change from '21-'22
2022
+0%
1 196
2021
791
2020
500
Customer accounts served
Change from '21-'22
2022
+0%
926m
2021
750m
2020
637m
Who is impacted?
Researchers are impacted directly through more effective tools to understand human biology. Patients are impacted indirectly through breakthroughs in treatments.
What are the impact considerations?
Additionality
By providing a truly unique technology to the market, Olink makes a major contribution to the research enabling advancements in precision medicine.
Risks
Olink’s impact depends in part on how its customers in academia and biopharma choose to use its tools. Olink can engage customers to help ensure that the research it enables translates into treatment innovations and eventually patient outcomes.